Literature DB >> 15239398

Sustained remissions with long-term weekly chlorambucil maintenance therapy in patients with mucosa-associated lymphoid tissue lymphoma.

Arumugam Manoharan1.   

Abstract

Five patients with mucosa-associated lymphoid tissue (MALT) lymphoma (Helicobacter pylori negative) were initially treated with daily chlorambucil (Chl, 0.06-0.08 mg/kg per day) and achieved complete remission (n = 4) or partial remission (n = 1). They were then given long-term weekly Chl as maintenance therapy with good results. One patient came off treatment and has remained in continued remission for 44 months. This simple, low-cost, and convenient approach deserves further evaluation in patients with MALT lymphoma and other indolent and incurable lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239398     DOI: 10.1532/ijh97.a20308

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

Review 1.  The gastric marginal zone B-cell lymphoma of MALT type.

Authors:  E Zucca; F Bertoni; E Roggero; F Cavalli
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

2.  Long-term remissions with weekly chlorambucil therapy in patients with intermediate-risk chronic lymphocytic leukaemia.

Authors:  A Manoharan
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

3.  Chemotherapy for MALTomas--are we back to where we started?

Authors:  Burton F Alexander
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

4.  Long-term maintenance therapy with weekly chlorambucil in patients with symptomatic or progressive follicular lymphoma.

Authors:  Arumugam Manoharan
Journal:  Leuk Lymphoma       Date:  2004-06

Review 5.  B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours.

Authors:  E Zucca; E Roggero; S Pileri
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

6.  Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients.

Authors:  C Thieblemont; Y Bastion; F Berger; C Rieux; G Salles; C Dumontet; P Felman; B Coiffier
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

7.  Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.

Authors:  Michaël Levy; Christiane Copie-Bergman; Catherine Traulle; Anne Lavergne-Slove; Nicole Brousse; Jean-François Flejou; A de Mascarel; François Hemery; Philippe Gaulard; Jean-Charles Delchier
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

8.  Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression.

Authors:  P Hammel; C Haioun; M T Chaumette; P Gaulard; M Divine; F Reyes; J C Delchier
Journal:  J Clin Oncol       Date:  1995-10       Impact factor: 44.544

9.  Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.

Authors:  Gerald Jäger; Peter Neumeister; Ruth Brezinschek; Thomas Hinterleitner; Wolfgang Fiebiger; Melitta Penz; Hans J Neumann; Brigitte Mlineritsch; Maria DeSantis; Franz Quehenberger; Andreas Chott; Christine Beham-Schmid; Gerald Höfler; Werner Linkesch; Markus Raderer
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.